Decoy Therapeutics Inc

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.